Selection of excipient, solvent and packaging to optimize the performance of spray-dried formulations: Case example fenofibrate

Drug Development and Industrial Pharmacy

Volumn 39, Issue 2, 2013, Pages 402-412

  Hugo, Marc ^a,b   Kunath, Klaus ^b   Dressman, Jennifer ^a  

^a GOETHE UNIVERSITY   (Germany)

^b MERCK KGAA   (Germany)

Author keywords

Biorelevant media; Dissolution behavior; Excipients; Fenofibrate; Long term stability; Solid dispersion; Spray drying

Indexed keywords

ACETONE; ACETONITRILE; ALCOHOL; CHLOROFORM; CRYSTALLIN; DICHLOROMETHANE; DRUG SOLVENT; EXCIPIENT; FENOFIBRATE; METHANOL; N,N DIMETHYLFORMAMIDE; POLYMER;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG PACKAGING; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; DRUG STRUCTURE; INFRARED SPECTROSCOPY; PARTICLE SIZE; SPRAY DRYING; VISCOSITY; X RAY POWDER DIFFRACTION;

DRUG COMPOUNDING; DRUG PACKAGING; EXCIPIENTS; FENOFIBRATE; HYPOLIPIDEMIC AGENTS; PARTICLE SIZE; SOLUBILITY;

EID: 84872449300     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.685176     Document Type: Article

References (100)

1. Benet LZ, Wu C, Custodio JM. Predicting drug absorption and the effects of food on oral bioavailability. Bulletin Technique Gattefosse 2006;99:9-16.
2. Prentis RA, Lis Y, Walker SR. (1988). Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). Br J Clin Pharmacol, 25:387-396.
3. Lipinski CA. Poor Aqueous Solubility-an Industry Wide Problem in Drug Discovery. Am Pharm Rev 2002;5:82-85.
4. Hancock BC, Zografi G. (1997). Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci, 86:1-12.
5. Helliwell M, Taylor D. (1993). Solid oral dosage forms. Prof Nurse, 8:313-317.
6. Corrigan DO, Healy AM, Corrigan OI. (2003). The effect of spray drying solutions of bendroflumethiazide/polyethylene glycol on the physicochemical properties of the resultant materials. Int J Pharm, 262:125-137. (Pubitemid 36966700)
7. Janssens S, de Armas HN, Roberts CJ, Van den Mooter G. (2008). Characterization of ternary solid dispersions of itraconazole, PEG 6000, and HPMC 2910 E5. J Pharm Sci, 97:2110-2120.
8. Patterson JE, James MB, Forster AH, Lancaster RW, Butler JM, Rades T. (2007). Preparation of glass solutions of three poorly water soluble drugs by spray drying, melt extrusion and ball milling. Int J Pharm, 336:22-34. (Pubitemid 46551551)
9. Van den Mooter G, Weuts I, De Ridder T, Blaton N. (2006). Evaluation of Inutec SP1 as a new carrier in the formulation of solid dispersions for poorly soluble drugs. Int J Pharm, 316:1-6. (Pubitemid 43765697)
10. Maas J, Kamm W, Hauck G. (2007). An integrated early formulation strategy-from hit evaluation to preclinical candidate profiling. Eur J Pharm Biopharm, 66:1-10. (Pubitemid 46412973)
11. Granero GE, Ramachandran C, Amidon GL. (2005). Dissolution and solubility behavior of fenofibrate in sodium lauryl sulfate solutions. Drug Dev Ind Pharm, 31:917-922. (Pubitemid 41540944)
12. Amidon GL, Lennernäs H, Shah VP, Crison JR. (1995). A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res, 12:413-420.
13. Najib J. (2002). Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation. Clin Ther, 24:2022-2050. (Pubitemid 36051529)
14. Pan X, Julian T, Augsburger L. Quantitative Measurement of Indomethacin Crystallinity in Indomethacin-Silica Gel Binary System Using Differential Scanning Calorimetry and X-ray Powder Diffractometry. AAPS Pharm Sci Tech 2007;7:Article 11.
15. Pan X, Julian T, Augsburger L. (2008). Increasing the dissolution rate of a low-solubility drug through a crystalline-amorphous transition: a case study with indomethacin [correction of indomethicin]. Drug Dev Ind Pharm, 34:221-231. (Pubitemid 351317152)
16. Jones RM. Particle size analysis by laser diffraction: ISO 13320, standard operating procedures, and Mie theory. American Laboratory 2003:44-47.
17. Shekunov BY, Chattopadhyay P, Tong HH, Chow AH. (2007). Particle size analysis in pharmaceutics: principles, methods and applications. Pharm Res, 24:203-227. (Pubitemid 46072181)
18. Dressman JB, Amidon GL, Reppas C, Shah VP. (1998). Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res, 15:11-22. (Pubitemid 28080861)
19. Zoeller T, Klein S. Simplified Biorelevant Media for Screening Dissolution Performance of Poorly Soluble Drugs. Dissolution Technologies 2007;14:8-13.
20. Council of Europe. Fenofibrate. In: Council of Europe, ed. European Pharmacopoeia 5th Edition. Strasbourg: Directorate for the Quality of Medicines of the Council of Europe, 2004:1581-1583.
21. ICH Expert Working Group. Stability Testing of New Drug Substances and Products Q1A(R2). ICH [Online] 2003. Available at: http://www.ich.org/products/ guidelines/quality/article/qualityguidelines. html. Accessed on 16 July 2011.
22. Shmeis RA, Wang Z, Krill SL. (2004). A mechanistic investigation of an amorphous pharmaceutical and its solid dispersions, part I: a comparative analysis by thermally stimulated depolarization current and differential scanning calorimetry. Pharm Res, 21:2025-2030. (Pubitemid 40941222)
23. Forster A, Hempenstall J, Tucker I, Rades T. (2001). Selection of excipients for melt extrusion with two poorly water-soluble drugs by solubility parameter calculation and thermal analysis. Int J Pharm, 226:147-161. (Pubitemid 32800790)
24. Chokshi RJ, Sandhu HK, Iyer RM, Shah NH, Malick AW, Zia H. (2005). Characterization of physico-mechanical properties of indomethacin and polymers to assess their suitability for hot-melt extrusion processs as a means to manufacture solid dispersion/solution. J Pharm Sci, 94:2463-2474. (Pubitemid 43081943)
25. Langer M, Höltje M, Urbanetz NA, Brandt B, Höltje HD, Lippold BC. (2003). Investigations on the predictability of the formation of glassy solid solutions of drugs in sugar alcohols. Int J Pharm, 252:167-179. (Pubitemid 36126625)
26. Marsac PJ, Shamblin SL, Taylor LS. (2006). Theoretical and practical approaches for prediction of drug-polymer miscibility and solubility. Pharm Res, 23:2417-2426. (Pubitemid 44511522)
27. Vasanthavada M, Tong WQ, Joshi Y, Kislalioglu MS. (2004). Phase behavior of amorphous molecular dispersions I: Determination of the degree and mechanism of solid solubility. Pharm Res, 21:1598-1606. (Pubitemid 41184390)
28. Van den Mooter G, Wuyts M, Blaton N, Busson R, Grobet P, Augustijns P et al. (2001). Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25. Eur J Pharm Sci, 12:261-269.
29. Six K, Verreck G, Peeters J, Brewster M, Van Den Mooter G. (2004). Increased physical stability and improved dissolution properties of itraconazole, a class II drug, by solid dispersions that combine fastand slow-dissolving polymers. J Pharm Sci, 93:124-131. (Pubitemid 38081820)
30. Couchman PR, Karasz FE. A Classical Thermodynamic Discussion of the Effect of Composition on Glass-Transition Temperatures. Macromolecules 1978;11:117-119.
31. Couchman PR. Compositional Variation of Glass-Transition Temperatures. 2. Application of the Thermodynamic Theory to Compatible Polymer Blends. Macromolecules 1978;11:1156-1161.
32. Schneider HA. Conformational Entropy Contributions to the Glass Temperature of Blends of Miscible Polymers. J Res Natl Inst Stand Technol 1997;102:229-248.
33. Kwei TK. The Effect of Hydrogen Bonding on the Glass Transition Temperatures of Polymer Mixtures. Journal of Polymer Science: Polymer Letters Edition 1984;22:307-313. (Pubitemid 14622322)
34. Kwei TK, Pearce EM, Pennacchia JR, Charton M. Correlation between the Glass Transition Temperatures of Polymer Mixtures and Intermolecular Force Parameters. Macromolecules 1987;20:1174-1176.
35. Tajber L, Corrigan OI, Healy AM. (2005). Physicochemical evaluation of PVP-thiazide diuretic interactions in co-spray-dried composites-analysis of glass transition composition relationships. Eur J Pharm Sci, 24:553-563. (Pubitemid 40387269)
36. ICH Expert Working Group. Impurities: Guideline for Residual Solvents Q3C(R5). ICH [Online] 2011 Available at: http://www.ich. org/products/ guidelines/quality/article/quality-guidelines.html. Accessed on 16 July 2011.
37. Hino T, Shimabayashi S, Ohnishi N, Fujisaki M, Mori H, Watanabe O et al. (2000). Development of a new type nozzle and spray-drier for industrial production of fine powders. Eur J Pharm Biopharm, 49:79-85. (Pubitemid 30009950)
38. Ozeki T, Beppu S, Mizoe T, Takashima Y, Yuasa H, Okada H. (2005). Preparation of two-drug composite microparticles to improve the dissolution of insoluble drug in water for use with a 4-fluid nozzle spray drier. J Control Release, 107:387-394. (Pubitemid 41393350)
39. Chen R, Okamoto H, Danjo K. (2008). Preparation of functional composite particles of salbutamol sulfate using a 4-fluid nozzle spray-drying technique. Chem Pharm Bull, 56:254-259. (Pubitemid 351463233)
40. Asada M, Takahashi H, Okamoto H, Tanino H, Danjo K. (2004). Theophylline particle design using chitosan by the spray drying. Int J Pharm, 270:167-174. (Pubitemid 38077097)
41. Corrigan DO, Corrigan OI, Healy AM. (2004). Predicting the physical state of spray dried composites: salbutamol sulphate/lactose and salbutamol sulphate/polyethylene glycol co-spray dried systems. Int J Pharm, 273:171-182. (Pubitemid 38317050)
42. Takeuchi H, Nagira S, Yamamoto H, Kawashima Y. (2005). Solid dispersion particles of amorphous indomethacin with fine porous silica particles by using spray-drying method. Int J Pharm, 293:155-164. (Pubitemid 40381089)
43. Columbano A, Buckton G, Wikeley P. (2003). Characterisation of surface modified salbutamol sulphate-alkylpolyglycoside microparticles prepared by spray drying. Int J Pharm, 253:61-70. (Pubitemid 36197831)
44. Vehring R, Foss WR, Lechuga-Ballesteros D. Particle formation in spray-drying. Aerosol Science 2007;38:728-746.
45. Vehring R. (2008). Pharmaceutical particle engineering via spray drying. Pharm Res, 25:999-1022.
46. Vogt M, Kunath K, Dressman JB. (2008). Dissolution enhancement of fenofibrate by micronization, cogrinding and spray-drying: comparison with commercial preparations. Eur J Pharm Biopharm, 68:283-288.
47. Jijun F, Lishuang X, Xiaoli W, Shu Z, Xiaoguang T, Xingna Z et al. (2011). Nimodipine (NM) tablets with high dissolution containing NM solid dispersions prepared by hot-melt extrusion. Drug Dev Ind Pharm, 37:934-944.
48. Maestrelli F, Zerrouk N, Cirri M, Mennini N, Mura P. (2008). Microspheres for colonic delivery of ketoprofen-hydroxypropylbeta-cyclodextrin complex. Eur J Pharm Sci, 34:1-11.
49. Brewster ME, Vandecruys R, Peeters J, Neeskens P, Verreck G, Loftsson T. (2008). Comparative interaction of 2-hydroxypropylbeta-cyclodextrin and sulfobutylether-beta-cyclodextrin with itraconazole: phase-solubility behavior and stabilization of supersaturated drug solutions. Eur J Pharm Sci, 34:94-103.
50. Council of Europe. Poly(vinyl acetate). In: Council of Europe, ed. European Pharmacopoeia 5th Edition. Strasbourg: Directorate for the Quality of Medicines of the Council of Europe, 2004:2271-2272.
51. Vogt M, Kunath K, Dressman JB. (2008). Dissolution improvement of four poorly water soluble drugs by cogrinding with commonly used excipients. Eur J Pharm Biopharm, 68:330-337.
52. Tanno F, Nishiyama Y, Kokubo H, Obara S. (2004). Evaluation of hypromellose acetate succinate (HPMCAS) as a carrier in solid dispersions. Drug Dev Ind Pharm, 30:9-17. (Pubitemid 38240471)
53. Al-Obaidi H, Brocchini S, Buckton G. (2009). Anomalous properties of spray dried solid dispersions. J Pharm Sci, 98:4724-4737.
54. Bain DF, Munday DL, Smith A. (1999). Solvent influence on spray-dried biodegradable microspheres. J Microencapsul, 16:453-474. (Pubitemid 29332733)
55. Dontireddy R, Crean AM. (2011). A comparative study of spraydried and freeze-dried hydrocortisone/polyvinyl pyrrolidone solid dispersions. Drug Dev Ind Pharm, 37:1141-1149.
56. Loftsson T, Brewster ME. (1996). Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci, 85:1017-1025. (Pubitemid 26338912)
57. Hancock BC, Zografi G. (1994). The relationship between the glass transition temperature and the water content of amorphous pharmaceutical solids. Pharm Res, 11:471-477. (Pubitemid 24144434)
58. Kauzmann W. The Nature of the Glassy State and the Behavior of Liquids at low Temperatures. Chem Rev 1948;43:219-256.
59. Hancock BC, Christensen K, Shamblin SL. (1998). Estimating the critical molecular mobility temperature (T(K)) of amorphous pharmaceuticals. Pharm Res, 15:1649-1651. (Pubitemid 28524571)
60. Leuner C, Dressman J. (2000). Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm, 50:47-60. (Pubitemid 30326688)
61. Brewster ME, Loftsson T. (2007). Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev, 59:645-666. (Pubitemid 47299263)
62. Rasenack N, Müller BW. Poorly Water-soluble Drugs for Oral Delivery-A Challenge for Pharmaceutical Development-Part II: Micronization technologies and complex formation. Pharm. Ind. 2005;67:447-451. (Pubitemid 40873659)
63. Stegemann S, Leveiller F, Franchi D, de Jong H, Lindén H. (2007). When poor solubility becomes an issue: from early stage to proof of concept. Eur J Pharm Sci, 31:249-261. (Pubitemid 47079001)
64. Pinnamaneni S, Das NG, Das SK. (2002). Formulation approaches for orally administered poorly soluble drugs. Pharmazie, 57:291-300. (Pubitemid 34517296)
65. Blagden N, de Matas M, Gavan PT, York P. (2007). Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv Drug Deliv Rev, 59:617-630. (Pubitemid 47285407)
66. Chaumeil JC. (1998). Micronization: a method of improving the bioavailability of poorly soluble drugs. Methods Find Exp Clin Pharmacol, 20:211-215. (Pubitemid 28255411)
67. Rasenack N, Müller BW. Poorly Water-soluble Drugs for Oral Delivery-A Challenge for Pharmaceutical Development-Part I: Physicochemical and biopharmaceutical background/Strategies in pharmaceutical development. Pharm. Ind. 2005;67:323-326. (Pubitemid 40568839)
68. Kesisoglou F, Panmai S, Wu Y. (2007). Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev, 59:631-644. (Pubitemid 47285408)
69. Stella VJ, Nti-Addae KW. (2007). Prodrug strategies to overcome poor water solubility. Adv Drug Deliv Rev, 59:677-694. (Pubitemid 47285410)
70. Tang B, Cheng G, Gu JC, Xu CH. (2008). Development of solid selfemulsifying drug delivery systems: preparation techniques and dosage forms. Drug Discov Today, 13:606-612.
71. Rasenack N, Müller BW. Poorly Water-soluble Drugs for Oral Delivery-A Challenge for Pharmaceutical Development-Part III: Drug delivery systems containing the drug molecularly dispersed/Aspects on in vitro and in vivo characterization. Pharm. Ind. 2005;67:583-591. (Pubitemid 40868113)
72. Sethia S, Squillante E. (2003). Solid dispersions: revival with greater possibilities and applications in oral drug delivery. Crit Rev Ther Drug Carrier Syst, 20:215-247. (Pubitemid 37237280)
73. Takahashi H, Chen R, Okamoto H, Danjo K. (2005). Acetaminophen particle design using chitosan and a spray-drying technique. Chem Pharm Bull, 53:37-41. (Pubitemid 40879832)
74. Figueiras A, Carvalho RA, Ribeiro L, Torres-Labandeira JJ, Veiga FJ. (2007). Solid-state characterization and dissolution profiles of the inclusion complexes of omeprazole with native and chemically modified beta-cyclodextrin. Eur J Pharm Biopharm, 67:531-539. (Pubitemid 47211912)
75. Jug M, Becirevic-Lacan M. (2004). Multicomponent complexes of piroxicam with cyclodextrins and hydroxypropyl methylcellulose. Drug Dev Ind Pharm, 30:1051-1060. (Pubitemid 39577997)
76. Koester LS, Mayorga P, Bassani VL. (2003). Carbamazepine/betaCD/HPMC solid dispersions. I. Influence of the spray-drying process and betaCD/HPMC on the drug dissolution profile. Drug Dev Ind Pharm, 29:139-144. (Pubitemid 36297024)
77. Koester LS, Mayorga P, Pereira VP, Petzhold CL, Bassani VL. (2003). Carbamazepine/betaCD/HPMC solid dispersions. II. Physical characterization. Drug Dev Ind Pharm, 29:145-154. (Pubitemid 36292937)
78. Jung JY, Yoo SD, Lee SH, Kim KH, Yoon DS, Lee KH. (1999). Enhanced solubility and dissolution rate of itraconazole by a solid dispersion technique. Int J Pharm, 187:209-218. (Pubitemid 29443901)
79. Al-Zoubi N, Alkhatib HS, Bustanji Y, Aiedeh K, Malamataris S. (2008). Sustained-release of buspirone HCl by co spray-drying with aqueous polymeric dispersions. Eur J Pharm Biopharm, 69:735-742.
80. Otsuka M, Onoe M, Matsuda Y. (1993). Hygroscopic stability and dissolution properties of spray-dried solid dispersions of furosemide with Eudragit. J Pharm Sci, 82:32-38. (Pubitemid 23148846)
81. Shimpi SL, Chauhan B, Mahadik KR, Paradkar A. (2005). Stabilization and improved in vivo performance of amorphous etoricoxib using Gelucire 50/13. Pharm Res, 22:1727-1734. (Pubitemid 41355913)
82. Chauhan B, Shimpi S, Paradkar A. (2005). Preparation and evaluation of glibenclamide-polyglycolized glycerides solid dispersions with silicon dioxide by spray drying technique. Eur J Pharm Sci, 26:219-230. (Pubitemid 41169805)
83. Ambike AA, Mahadik KR, Paradkar A. (2004). Stability study of amorphous valdecoxib. Int J Pharm, 282:151-162. (Pubitemid 39178492)
84. Kai T, Akiyama Y, Nomura S, Sato M. (1996). Oral absorption improvement of poorly soluble drug using solid dispersion technique. Chem Pharm Bull, 44:568-571. (Pubitemid 26103123)
85. Chen R, Tagawa M, Hoshi N, Ogura T, Okamoto H, Danjo K. (2004). Improved dissolution of an insoluble drug using a 4-fluid nozzle spray-drying technique. Chem Pharm Bull, 52:1066-1070. (Pubitemid 41679544)
86. Cilurzo F, Minghetti P, Casiraghi A, Montanari L. (2002). Characterization of nifedipine solid dispersions. Int J Pharm, 242:313-317.
87. Mizoe T, Beppu S, Ozeki T, Okada H. (2007). One-step preparation of drug-containing microparticles to enhance the dissolution and absorption of poorly water-soluble drugs using a 4-fluid nozzle spray drier. J Control Release, 120:205-210. (Pubitemid 47058639)
88. Palmieri GF, Cantalamessa F, Di Martino P, Nasuti C, Martelli S. (2002). Lonidamine solid dispersions: in vitro and in vivo evaluation. Drug Dev Ind Pharm, 28:1241-1250. (Pubitemid 35416653)
89. Ambike AA, Mahadik KR, Paradkar A. (2005). Spray-dried amorphous solid dispersions of simvastatin, a low tg drug: in vitro and in vivo evaluations. Pharm Res, 22:990-998. (Pubitemid 40898109)
90. Dhumal RS, Shimpi SL, Paradkar AR. (2007). Development of spray-dried co-precipitate of amorphous celecoxib containing storage and compression stabilizers. Acta Pharm, 57:287-300. (Pubitemid 47429183)
91. Weuts I, Kempen D, Decorte A, Verreck G, Peeters J, Brewster M et al. (2004). Phase behaviour analysis of solid dispersions of loperamide and two structurally related compounds with the polymers PVP-K30 and PVP-VA64. Eur J Pharm Sci, 22:375-385. (Pubitemid 38953896)
92. Tewa-Tagne P, Briançon S, Fessi H. (2007). Preparation of redispersible dry nanocapsules by means of spraydrying: development and characterisation. Eur J Pharm Sci, 30:124-135. (Pubitemid 46157175)
93. Ozeki T, Beppu S, Mizoe T, Takashima Y, Yuasa H, Okada H. (2006). Preparation of polymeric submicron particle-containing microparticles using a 4-fluid nozzle spray drier. Pharm Res, 23:177-183. (Pubitemid 43214674)
94. Hu J, Johnston KP, Williams RO 3rd. (2003). Spray freezing into liquid (SFL) particle engineering technology to enhance dissolution of poorly water soluble drugs: organic solvent versus organic/aqueous co-solvent systems. Eur J Pharm Sci, 20:295-303. (Pubitemid 37338535)
95. Wong SM, Kellaway IW, Murdan S. (2006). Enhancement of the dissolution rate and oral absorption of a poorly water soluble drug by formation of surfactant-containing microparticles. Int J Pharm, 317:61-68. (Pubitemid 43866347)
96. Weuts I, Kempen D, Verreck G, Decorte A, Heymans K, Peeters J et al. (2005). Study of the physicochemical properties and stability of solid dispersions of loperamide and PEG6000 prepared by spray drying. Eur J Pharm Biopharm, 59:119-126. (Pubitemid 39573443)
97. Fouad EA, El-Badry M, Mahrous GM, Alanazi FK, Neau SH, Alsarra IA. (2011). The use of spray-drying to enhance celecoxib solubility. Drug Dev Ind Pharm, 37:1463-1472.
98. Yassin AE, Alanazi FK, El-Badry M, Alsarra IA, Barakat NS, Alanazi FK. (2009). Preparation and characterization of spironolactoneloaded gelucire microparticles using spray-drying technique. Drug Dev Ind Pharm, 35:297-304.
99. Serajuddin AT. (2007). Salt formation to improve drug solubility. Adv Drug Deliv Rev, 59:603-616. (Pubitemid 47285406)
100. Dürrigl M, Kregar ML, Hafner A, Klaric MŠ, Filipovic-Grcic J. (2011). Mupirocin calcium microencapsulation via spray drying: feed solvent influence on microparticle properties, stability and antimicrobial activity. Drug Dev Ind Pharm, 37:1402-1414.